Artimplant Interim Report January-September, 2008 Conference Call on November 11, 2008, 11:00 AM (GMT+1)

Artimplant Interim Report January-September, 2008 Conference Call on November
11, 2008, 11:00 AM (GMT+1)

Västra Frölunda, Sweden, November 6, 2008 
CEO Hans Rosén and CFO Lars-Johan Cederbrant present the interim report
January-September, 2008 through a conference call on November 11, 2008, 11:00 AM
(GMT+1)

The presentation will be in Swedish. 

Date: Tuesday November 11, 2008
Time: 11:00 AM Central European Time (GMT+1) 

Dial in numbers: 

Swedish participants: +46 (0)8 505 598 53 
UK participants: +44 (0)20 3043 2436 
US participants: +1 866 458 40 87 

A presentation in PDF format will be available on Artimplant's website
www.artimplant.com a couple of minutes before the conference call starts. 

Please note that Artimplant's interim report January-September, 2008 will be
distributed with a press release on November 11, 2008, 8:45 AM Central European
Time (GMT+1).

For further information, please contact:
Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on November 6, 2008 at 10:30am (GMT+1).